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application of ICPMS (79/81Br), HPLC-ICPMS & HPLC-oaTOFMS
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Abstract
1. An excretion balance study was performed following i.p. administration of 4-bromoaniline
(50mg kg1) to bile-cannulated rats, using bromine-detected (79/81Br) ICPMS for quantifi-
cation. Approximately 90% of the dose was recovered in urine (68.9 ± 3.6%) and bile
(21.4 ± 1.4%) by 48 h post-administration.
2. HPLC-ICPMS (79/81Br) was used to selectively detect and profile the major urinary and biliary-
excreted metabolites and determined that the 0–12 h urine contained at least 21 brominated
metabolites with 19 bromine-containing peaks observed in the 6–12 h bile samples.
3. The urinary and biliary metabolites were subsequently profiled using HPLC-oaTOFMS.
By exploiting the distinctive bromine isotope pattern ca. 60 brominated metabolites
were detected in the urine in negative electrospray ionisation (ESI) mode while bile
contained ca. 21.
4. While a large number of bromine-containing metabolites were detected, the profiles were
dominated by a few major components with the bulk of the 4-bromoaniline-related material
in urine accounted for by 4-bromoanaline O-sulfate (75% of the total by ICPMS, 84% by
TOFMS). In bile a hydroxylated N-acetyl compound was the major metabolite detected,
forming some 65% of the 4-bromoaniline-related material by ICPMS (37% by TOFMS).
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Introduction
Anilines are important intermediates in many industrial
processes including the synthesis of drugs and pesticides.
As part of studies aimed at developing in vivo quantitative
structure relationships for this class of compounds (Athersuch
et al., 2013; Scarfe et al., 2002a), particularly with regard to
the production of unusual N-oxanilic acid metabolites, we
have investigated the metabolic fate of 4-bromoaniline in
the rat (Abou-Shakra et al., 2002; Major et al., 2003a,b;
Nicholson et al., 2000; Scarfe et al., 2002b). These qualita-
tive studies, which were limited to a study of the metabolites
excreted via the urine, revealed a surprisingly complex
metabolic fate for such a relatively simple structure. We
have therefore undertaken further studies in order to obtain a
more complete, and quantitative, metabolic profile for
4-bromoaniline, in bile-cannulated rats, with the additional
aim of further characterising and identifying the metabolites
of the compound. Previously, we have demonstrated the utility
of using bromine-specific ICPMS for obtaining quantitative
excretion-balance measurements and metabolic profiles for
bromine-containing compounds (Packert Jensen et al., 2005;
Smith et al., 2008) on urine and bile, etc. Here quantitative
and qualitative profiling of biofluids has been performed
using HPLC-ICPMS with bromine-specific detection, while
HPLC-oaTOFMS was used for metabolite identification. The
study provides a further demonstration of the utility of
Br-ICPMS as a quantitative tool for in vivo metabolism
studies without the need for the synthesis of radiolabelled
tracers (see also, e.g. Cuyckens et al., 2008; Gammelgaard
et al., 2008; Meermann et al., 2012).
Methods and materials
Chemicals
4-Bromoaniline, purity 98%, was obtained from Aldrich
(Poole, UK) and was used as received. Bromobenzene, purity
99%, was also obtained from Aldrich. Solvents for HPLC
were of high purity HPLC grade and were obtained from
Fisher Scientific UK Ltd. (Loughborough, UK).
This is an Open Access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License
(http://creativecommons.org/Licenses/by-nc-nd/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium,
provided the original work is properly cited, and is not altered,
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Animals and dosing
Three male Wistar-derived rats (200–250 g) were fitted with
biliary cannulae. The surgical procedure involved an incision
down the abdomen just below the liver. The intestine was
moved sideways from the lower liver to reveal the hepatic
artery and bile duct. The bile duct was isolated and
straightened and a Portex polyethylene catheter (0.28mm
i.d.) inserted approximately 5mm into the bile duct and firmly
ligated. The abdominal cavity was then closed with surgical
wire and the catheter passed under the skin of the lower
abdomen and out through a puncture made in the tail. The
skin of the abdomen was closed with surgical wire. The
animals were anaesthetised with Fluothane (AstraZeneca,
Macclesfield, UK) prior to and during bile duct cannulation.
During the recovery period the bile duct cannula was secured
with a harness from the tail of the rat to the roof of the
metabolism cage.
The animals were acclimatised in metabolism cages for
72 h prior to dosing and were permitted free access to food
(R&M No. 1 Modified Irradiated Diet) and water throughout
the study. The water was supplemented with glucose, NaCl
and KCl for 24 h prior to surgery until 48 h after surgery, then
with only NaCl and KCl until the end of the study. The rats
were dosed with 4-bromoaniline, ip, at 50mg kg1 in ethanol-
water (1:1 v/v), at a concentration of 50mgmL1.
Urine and bile were collected over solid CO2 into sterile
containers for the periods 0–12, 12–24 and 24–48 h and 0–6,
6–12, 12–24 and 24–48 h post-dosing, respectively. The
samples were stored frozen (20 C) until analysis.
At the end of the study, animals were sacrificed by
halothane inhalation with confirmation by cervical disloca-
tion. The study was subject to internal ethical review and all
animal procedures and treatments were carried out in
accordance with approved animal licenses and guidelines
issued by the British Home office [Animals (Scientific
Procedures) Act (1986)].
Excretion balance via quantification of 79Br by ICPMS
Standard curve preparation
Concentrations of Br-containing material in urine and bile
were determined by reference to a calibration curve prepared
using bromobenzene. Ten calibration standards were prepared
in control urine and bile over the range 0.00004 to
4mgmL1. For the construction of the calibration curves,
50 mL of each standard was directly injected, in duplicate, into
a Platform ICP mass spectrometer (Micromass UK Ltd.,
Wythenshawe, UK), tuned to monitor 79Br and 81Br, and the
response measured over 1.5min. The peak areas were then
taken and used to construct standard curves for urine and bile.
Biofluid analysis for 79Br by ICPMS
Urine and bile samples (25mL or 50 mL) from each time point
were injected, in duplicate, directly into the Platform ICP
mass spectrometer monitoring both 79Br and 81Br isotopes.
The response was measured over 1.5min and the concen-
tration of Br was then determined by reference to the
calibration curve.
The flow of the nebuliser gases and the operating and
acquisition conditions of the ICP mass spectrometer are
shown in Table 1. MassLynxTM software was used for
instrument control, data acquisition and handling.
HPLC-ICPMS (79/81Br)
For metabolite profiling and quantification using HPLC-
ICPMS an Alliance 2695 separation module (Waters
Corporation, Watford, UK) coupled to a Platform ICP mass
spectrometer (Micromass UK Ltd.) tuned to monitor 79Br and
81Br was used. In order to avoid excessive carbon build-up on
the cones of the instrument the nebuliser gas was mixed to 5%
v/v oxygen in argon using an onboard mass flow controller.
Additionally oxygen was used as the hexapole auxillary gas.
The flow of the nebuliser gases and the operating and
acquisition conditions of the ICP mass spectrometer are
shown in Table 2. The chromatographic separation was
carried out using a Hichrom H5BDS C18 column,
(250 4.6mm) (Hichrom Ltd., Reading, UK) packed with
5-mm particles, using a linear reversed-phase gradient method
based on 0.01M ammonium formate (solvent A) and
methanol (solvent B) as follows; 0 to 10min 5% B, 10 to
35min 5 to 60% B, 35 to 40min 60 to 80% B, then from 40 to
50min 80 to 5% B. The flow rate was 1mLmin1, which was
split to 200 mL before entering the mass spectrometer. A total
of 20 mL injections of urine or bile samples from one animal
were made. MassLynxTM (version 4.0) software was used for
instrument control, data acquisition and handling.
HPLC-oaTOFMS
For metabolite characterisation and structure determination,
HPLC-oaTOFMS was performed using an Alliance 2695
separation module (Waters Corporation) coupled to a
Micromass LCT Premier
TM
orthogonal acceleration time of
flight mass spectrometer (oa-TOFMS) (Micromass UK Ltd).
The chromatographic separation was carried out on a C18
Symmetry column (250 4.6mm) (Waters Corporation),
fitted with a guard column (2 cm 3.9mm 5mm) (Waters
Corporation) using a linear reversed-phase gradient method
based on 0.01M ammonium formate (solvent A) and
methanol (solvent B) as follows; 0 to 10min 0% B,
Table 2. Instrument operating conditions for (HPLC)-ICPMS.
Cool gas 13.0 L min1 Plasma power not recorded
Intermediate gas 0.7 L min1 Acquisition mode SIR
Nebuliser gas 0.75 L min1 Dwell time 0.2 s
Helium gas 2.0mLmin1 Masses monitored 79, 81
Hydrogen gas 2.0mLmin1 Total analysis time 15.5min then
Hexapole auxiliary
gas (O2)
0.2mLmin1 50.5min
Table 1. Instrument operating conditions for the ICPMS.
Cool gas 18.00mLmin1 Plasma power 1600W
Intermediate gas 0.80mLmin1 Acquisition mode SIR
Nebuliser gas 0.60mLmin1 Dwell time 0.5 s
Helium gas 2.0mLmin1 Masses monitored 79, 81
Hydrogen gas 2.0mLmin1 Total analysis time 1.5min
Hexapole auxiliary gas 0mLmin1
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10 to 35min 0 to 60% B, 35 to 40min 60 to 80% B, then from
40 to 50min 80 to 0% B, at a flow rate of 1mmLmin1. The
flow was split 4:1 before entering the mass spectrometer.
Prior to performing all HPLC-MS experiments, the mass
spectrometer was calibrated in both positive and negative ion
electrospray. To carry out exact mass measurement of the
analytes, a reference lockmass was infused into the eluent
stream via a LockSprayTM, the lockspray switch time was
10 s. Leucine enkephalin (C28H37N5O7) was used as it
produces both a positive and negative ion
([M+H]+¼ 556.2771, [M-H]¼ 554.2615). Data were
acquired over 80–800 m/z at an acquisition rate of 1 spectrum
per second. Capillary voltages for sample ionisation were set
to 3000 kV, and a sample cone voltage of 30V was used for
all experiments. Urine samples were diluted one in four with
aqueous buffer, and bile samples were diluted one in three
with aqueous buffer. The injection volume was 30 mL, and a
blank injection was made after each sample analysis. The
separation was also monitored by UV spectroscopy over the
range 210–400 nm via UV-DAD (996 PDA, Waters
Corporation) photodiode array detector. MassLynxTM (ver-
sion 4.0, Waters Corporation) software was used for instru-
ment control, data acquisition and handling.
Results and discussion
ICPMS-determined bromine excretion balance
The calibration curves constructed for bromine in urine
and bile using ICPMS were linear over the range 0.00004 to
4mgmL1 (urine R2¼ 0.998, bile R2¼ 0.996) and all of the
bromine responses for the subsequent biofluid samples fell
within the range of the standard curves.
The bromine excretion data for the urine and bile of the
three animals dosed with 50mg kg1 of 4-bromoaniline are
shown in Table 3. As these data show, excretion was rapid
with a total urinary recovery of 68.9± 3.6% of the dose
achieved by 48 h after dosing and 21.4± 1.4% in the bile by
24 h post-dose. Br-containing material was not detected above
background noise in the 24–48 h bile samples. The total
recovery of 4-bromoaniline following intraperitoneal admin-
istration at 50mg kg1 up to 48 h post-dose was therefore
90.3± 3.8%.
Typical urinary and biliary HPLC-ICPMS (total ion count,
79Br and 81Br) profiles for the Br-containing metabolites of
4-bromoaniline in the rat, for the study period 0–48 h post-
dose for urine and bile are shown in Figures 1 and 2,
respectively. The urinary profiles obtained in these bile-
cannulated animals were similar to those obtained from non-
cannulated rats using HPLC-ICPMS in the previous
investigations of the metabolism of 4-bromoaniline (Abou-
Shakra et al., 2002; Nicholson et al., 2000; Scarfe et al.,
2002b). The principal metabolite, accounting for ca. 75% of
the total, eluted at 23min. (corresponding to the O-sulphate,
metabolite VII, see later) and this, together with two other
peaks, eluting at 30.0 and 32.5min, made up the majority of
the brominated material excreted during the 0–12 h period.
However, at least 21 bromine-containing peaks can be
observed in the ‘‘bromatogram’’ for this time point. The
12–24 h profile was similar to the 0–12 h sample in that it
contained the same three major peaks, though the metabolite
eluting at ca. 30.0min. now dominated the profile (Figure 1).
The 24–48 h sample contained much less in the way of
bromine-containing material with the metabolites eluting at
23min and 30min, respectively, accounting for the majority
(Figure 1). The bromatograms for bile (Figure 2) showed a
major metabolite eluting at 32.2min, accounting for ca. 65%
of the total, with another significant Br-containing component
at a retention time of 25.0min. In addition to these two
major components the 6–12 h bile bromatogram contained at
least a further 19 brominated metabolites. The peak eluting at
ca. 22min (highlighted in these traces) was identified as an
artefact (supporting evidence not included).
Metabolite identification using HPLC-oaTOFMS
HPLC-oaTOFMS was then employed to characterise and
identify the Br-containing metabolites of 4-BrA. Typical total
ion current traces (negative ESI data) for urine and bile are
shown in Figure 3(a) and (b). While the TICs are complex the
distinctive bromine isotope pattern (79Br:81Br in the ratio
50.69:49.31) enabled the peaks relating to the 4-bromoaniline
metabolites to be easily distinguished from endogenous
components. Thus, HPLC-oaTOFMS, in both positive and
negative ESI, and using a sensitivity cut-off of 20% threshold
for the background noise to determine the presence of a
bromine isotope pattern, enabled the detection of some 60 Br-
containing compounds in negative ESI (Figure 3a). This
probably does not represent the total of Br-containing species
present and the use of a less stringent background level as a
cut off would no doubt have increased these numbers
substantially. The presence of the isotope pattern resulting
from the presence of bromine atoms means, providing that it
is not lost via metabolism, that it is possible to produce a
highly selective trace of 4-bromoaniline metabolites by
stripping out all of those signals that do not contain this
pattern. A representative trace produced in this way for urine
is shown in Figure 4. Such MS-generated ‘‘isotopograms’’ for
the bromine-containing metabolites of 4-BrA provide an
Table 3. Dose recovery in urine and bile (48 h) after ip administration of 4-bromoaniline determined by Br-detected ICPMS.
URINE BILE
0–12 h 12–24 h 24–48 h Total 0–6 h 6–12 h 12–24 h Total Total
Rat 1 37.3 13.6 19.0 69.9% 8.3 7.7 7.1 23.1% 93.0%
Rat 2 35.6 20.4 8.9 64.9% 7.5 6.4 7.1 21.0% 85.9%
Rat 3 42.0 17.6 12.5 72.1% 5.4 6.3 8.6 20.3% 92.4%
Total 68.9± 3.6% 21.5± 1.4% 90.4± 3.8%
DOI: 10.3109/00498254.2015.1007491 The metabolism of 4-bromoaniline by ICPMS 3
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interesting alternative to Br-detected ICPMS for specifically
visualising metabolite profiles where access to ICPMS is not
available. However, it should be borne in mind that while
useful for detection, the potential differences in ionisation
efficiency between metabolites may, unlike the ICPMS
profiles, result in their being no more quantitative than any
HPLC-MS profile.
Clearly, based on the quantitative profiles produced using
HPLC-ICPMS, the vast bulk of these compounds were
present only in trace amounts. The more abundant species,
based on peak area by HPLC-oaTOFMS, are listed in Table 4,
which also provides suggested atomic compositions and
identifications where possible (the metabolites are listed in
order of increasing mass). Exact mass determination in full
scan mode was used to aid in the identification of the putative
metabolites and provide an elemental composition. An
example of this process can be seen in Figure 5 where the
negative ESI mass spectrum for the N-oxanilic acid metab-
olite (IX) present in urine (eluting at a retention time of ca.
32min) is shown at m/z 241.9/243.9. The exact mass
determination for the m/z 241.9 ion gave 241.9466, which is
consistent with a molecular formula of C8H6NO3
79Br. The
loss of 72 amu, clearly visible in the mass spectrum, is due to
the oxalic acid fragment. As would be expected on the basis
of the similarity of the bromatograms obtained for urine
between this and the previous study (Scarfe et al., 2002b) the
major metabolite present in the urine was confirmed as the
2-hydroxysulphate of 4-BrA, eluting at ca. 27min (metabolite
VII). In addition to the previously identified metabolites, such
as the mercapturate (metabolite X), we characterised a further
10 species to provide a total of 17 characterised urinary
components related to the administered 4-bromoaniline.
As noted earlier, the metabolites of 4-BrA excreted in the
bile have not been previously characterised. The bromato-
grams of bile from these animals showed a much simpler
profile than urine with a small number of major metabolites.
In the case of bile the major brominated component detected,
eluting at 35.09min was a hydroxy- (most probably the
2-hydroxy) N-acetylated metabolite (XII) which comprised
some 65% of the 4-bromoaniline-related material present
overall, by ICPMS (Table 5 for m/z data). One of the other
4-BrA-related components, metabolite (XI), observed in the
TIC, eluting at 33.57min, (was also detected in urine) showed
a molecular ion [M-H] at m/z 330.9780/332.9777 (79/81Br)
corresponding to a molecular formula of C11H13N2O3SBr
which is consistent with the presence of a cysteinyl conjugate.
Examination of the fragmentation of this metabolite showed
the loss of the CH2CH(COOH)NH2 group to give the
fragment ion 245.9415 (81Br). However, the observed frag-
mentation was not consistent with ring-based modification,
Figure 1. HPLC-ICPMS profiles (79Br &
81Br, TIC) of urine from a rat dosed at
50mg kg1 with 4-bromoaniline. See
Tables 4 and 5 and Figure 6 for key to peak
identities and structures.
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suggesting that this metabolite is most likely a cysteinyl
conjugate formed following production of a glutathione
conjugate to a reactive hydroxy-sulphate of the glycoanilide
as previously seen for the mercapturate detected in urine (also
Scarfe et al., 2002b). As with urine, many other bromine-
containing peaks were observed in the biliary HPLC-
oaTOFMS profiles, recognisable by the bromine isotope
fingerprint and these are listed in Table 5, with suggested
biotransformations (see also Figure 6 for a schematic of the
biotransformations of 4-bromoaniline).
Comparison of the HPLC-ICPMS bromatograms against
the HPLC-TOFMS TICs for both urine and bile enabled the
relative proportions of the metabolites to be determined in
both sample types. While not identical both methods gave
similar results. Predictably, the retention times did not match
between the two chromatographic systems, with the metab-
olites eluting a consistent 3.8min later in the HPLC-TOFMS
system, but peaks were able to be identified none-the-less,
through comparison and overlay (illustrations not included)
and establishing the principal metabolites. The 2-hydroxysul-
phate (metabolite VII), seen in previous studies to be the
major component in urine (Scarfe et al., 2002b) accounted for
ca. 75% of the total by Br-selective ICPMS and 84% by
TOFMS. The N-acetyl-O-glucuronide (metabolite VIII)
accounted for ca. 9% by ICPMS and 5% by TOFMS). In
the case of the biliary profiles the major Br-containing
component in the 6–12 h bile – the hydroxylated N-acetyl
compound (XII) – made up 65% of the total by ICPMS and
37% by TOFMS.
As we, and others have shown elsewhere, the presence of
an ICP-detectable atom such as bromine (Abou Shakra et al.,
2002; Marshall et al., 2002; Nicholson et al., 2000, 2001;
Packert Jensen et al., 2005; Smith et al., 2008), iodine
(Duckett et al., 2003, 2007; Packert Jensen et al., 2004a),
sulphur (Corcoran et al., 2000; Gika et al., 2009; Packert
Jensen et al., 2004b) and, to a lesser extent chlorine
(Corcoran et al., 2000; Duckett et al., 2003, 2006) in a
x enobiotic readily allows for the element specific detection
and quantification of metabolites. Providing that the atom
being measured is not lost through metabolism determining
the concentrations of, for example, bromine in samples such
as urine and bile is easily accomplished, allowing the ready
determination of the time course of excretion of compound-
related material. Subsequent element-specific metabolite
profiling via HPLC-ICPMS then provides a quantitative
picture of the relative proportions of the metabolites present to
be obtained. When combined with conventional HPLC-MS
results in both metabolite quantification and identification
without the need for the use of radiotracers. Clearly, most
compounds do not contain appropriate elements to enable this
technical opportunity to be widely used. However, where such
a possibility exists the benefits are clear.
Figure 2. HPLC-ICPMS profiles (79Br &
81Br, TIC) of bile from a rat dosed at 50mg
kg1 with 4-bromoaniline (artefact is high-
lighted). See Tables 4 and 5 and Figure 6 for
key to peak identities and structures.
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Figure 3. HPLC-oa-TOFMS (TIC) profiles of
0–12 h urine (A), and 0–6 h bile (B) of a rat
dosed at 50mg kg1 with 4-bromoaniline,
metabolite peaks are indicated. See Tables 4
and 5 and Figure 6 for key to peak identities
and structures.
Figure 4. A bromine-isotopogram generated
for a 0–6 h urine sample from a 4-bromoani-
line-dosed rat. See Tables 4 and 5 and
Figure 6 for key to peak identities and
structures.
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Conclusions
The use of ICPMS, with direct injection of urine and bile
samples has enabled a quantitative excretion balance study
to be performed in bile-cannulated rats based on the
selective detection of bromine. Subsequent metabolic
profiling with HPLC-ICPMS and HPLC-oaTOFMS allowed
the generation of metabolite profiles for both biofluids, and
the identification of the major metabolites. The combination
of these techniques has enabled the metabolic fate of
4-bromoaniline in the bile-cannulated rat to be characterised
without the need to employ radiolabeled material as a
tracer.
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Table 4. Detected metabolites of 4-bromoaniline in urine using negative ion electrospray mode.
Metabolite name Formula MW mDa ppm Time (mins) Peak area (TIC)
Hydroxylation C6H6NOBr 185.9550 0.5 2.5 29.97 1535
2Hydroxylation C6H6NO2Br 201.9504 0 0 26.5 1935
2Hydroxylation C6H6NO2Br 201.9505 0.1 0.5 24.29 1166
N-Acetylation XIII C8H8NOBr 211.9709 0.2 1.1 37.74 1448
Hydroxylation + Acetylation XII C8H8NO2Br 227.9662 0.2 0.7 31.38 61065
Oxanilicacid IX C8H6NO3Br 241.9466 1.3 5.3 32.32 1992
2Hydroxylations + N-Acetylation C8H8NO3Br 243.9607 0.3 1 30.77 1896
2Hydroxylations + N-Acetylation C8H8NO3Br 243.9609 0.1 0.2 29.02 332
O-Sulfate conjugation VII C6H6NO4SBr 265.9119 0.4 1.5 27.04 933959
Cysteine conjugate XI C11H13N2O3SBr 330.9735 1.7 5.2 37.33 130
Hydroxylation + glucuronide conjugation III C12H14NO7Br 361.9876 0 0.1 25.36 17422
Hydroxylation + glucuronide conjugation III C12H14NO7Br 361.9892 1.6 4.5 30.16 2018
N-Acetylcysteine conjugation + sulfate conjugation C11H13N2O5S2Br 394.9340 3.1 7.9 37.55 811
N-Acetyl +O-Glucuronide VIII C14H16NO8Br 403.9972 0.9 2.3 28.29 29887
N-Acetyl +O-Glucuronide VIII C14H16NO8Br 403.9984 0.3 0.7 31.9 58238
N-Acetyl +Hydroxylation+O-glucuronide conjugation C14H16NO9Br 419.9928 0.2 0.5 21.59 1071
O-Glucuronide+ Sulfate conjugation II C12H14NO10SBr 441.9446 0.2 0.45 22.73 661
Figure 5. Negative ion mass spectrum and
structure of metabolite IX (4-bromo N-
oxanilic acid), eluting at 32.32min in the
urine.
100 150 200 250 300 350 400 450 500 550 600 650 700 750 800
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100
%
241.9460
169.9629
110.9758 172.9638
508.8820244.9483
390.9809309.9355245.9480 486.9074 775.8132511.8832 617.9431 753.7858
NH
Br
O
O
OH
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m/z 241.9/243.9
4-Bromoaniline N-oxanilic acid 
Table 5. Biliary metabolites of 4-bromoaniline detected using negative ion electrospray mode.
Metabolite name Formula MW mDa ppm Time (mins) Peak area (TIC)
N-acetylation XIII C8H8NOBr 211.9717 0.6 2.7 37.75 1461
N-Acetylation+Hydroxylation XII C8H8NO2Br 227.9660 0 0.2 35.09 1727
N-Acetylation+Hydroxylation XII C8H8NO2Br 227.9666 0.6 2.4 27.66 1470
N-Acetylation+Hydroxylation XII C8H8NO2Br 227.9672 1.2 5.1 32.93 500
Cysteine conjugate XI C11H13N2O3SBr 330.9772 2 5.9 33.57 6317
N-Acetylation+O-Glucuronide conjugation VIII C14H16NO8Br 403.9987 0.6 1.4 27.66 5010
N-Acetylation+O-Sulphate IV & V C8H8NO5SBr 307.9246 1.7 5.6 32.66 753
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